Precision Biosciences (DTIL) Revenue (2018 - 2026)
Precision Biosciences (DTIL) posted quarterly Revenue of $10.8 million for Q1 2026, up 37272.41% year-over-year from N/an in Q1 2025, and down 68.31% quarter-over-quarter from $34.2 million in Q4 2025.
Precision Biosciences (DTIL) Revenue (2018 - 2026) Analysis & Trends
Precision Biosciences (DTIL) has reported Revenue for 9 consecutive years, with $10.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Revenue rose 37272.41% year-over-year to $10.8 million; the TTM figure through Mar 2026 stood at $45.1 million (down 11.87% YoY), while the FY2025 annual figure was $34.3 million, down 50.12% from the prior year.
- Revenue eased to $10.8 million in Q1 2026 per DTIL's latest filing, from $34.2 million in the prior quarter.
- Across five years, Revenue topped out at $49.9 million in Q2 2024 and bottomed at $13000.0 in Q3 2025.
- Historically, Revenue has averaged $11.0 million across 5 years, with a median of $7.4 million in 2022.
- Annual changes were most pronounced in 2025 — Revenue sank 99.96% — and 2026, when it jumped 37272.41%.
- Precision Biosciences' Revenue stood at $10.6 million in 2022, then tumbled by 33.59% to $7.0 million in 2023, then slumped by 90.93% to $638000.0 in 2024, then jumped by 5261.13% to $34.2 million in 2025, then plunged by 68.31% to $10.8 million in 2026.
- Business Quant data shows DTIL's Revenue at $10.8 million in Q1 2026, $34.2 million in Q4 2025, and $13000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 145.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.71 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.29 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 1.06 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 425.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 674.14 Mn |
| 10 | Precision Biosciences | 228.31 Mn | 140.77 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.84 Mn |
| Dec 31, 2025 | 34.20 Mn |
| Sep 30, 2025 | 13,000.00 |
| Jun 30, 2025 | 18,000.00 |
| Mar 31, 2025 | 29,000.00 |
| Dec 31, 2024 | 638,000.00 |
| Sep 30, 2024 | 576,000.00 |
| Jun 30, 2024 | 49.90 Mn |
| Mar 31, 2024 | 17.58 Mn |
| Dec 31, 2023 | 7.04 Mn |
| Sep 30, 2023 | 13.12 Mn |
| Jun 30, 2023 | 19.79 Mn |
| Mar 31, 2023 | 8.78 Mn |
| Dec 31, 2022 | 10.60 Mn |
| Sep 30, 2022 | 7.36 Mn |
| Jun 30, 2022 | 3.82 Mn |
| Mar 31, 2022 | 3.32 Mn |
| Dec 31, 2021 | 6.34 Mn |
| Sep 30, 2021 | 24.04 Mn |
| Jun 30, 2021 | 68.81 Mn |